<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101465400</journal-id>
<journal-id journal-id-type="pubmed-jr-id">34171</journal-id>
<journal-id journal-id-type="nlm-ta">Sci Signal</journal-id>
<journal-id journal-id-type="iso-abbrev">Sci Signal</journal-id>
<journal-title-group>
<journal-title>Science signaling</journal-title>
</journal-title-group>
<issn pub-type="ppub">1945-0877</issn>
<issn pub-type="epub">1937-9145</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27245614</article-id>
<article-id pub-id-type="pmc">4924540</article-id>
<article-id pub-id-type="doi">10.1126/scisignal.aad8463</article-id>
<article-id pub-id-type="manuscript">NIHMS797527</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The 4E-BP–eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>So</surname>
<given-names>Lomon</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Jongdae</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Palafox</surname>
<given-names>Miguel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mallya</surname>
<given-names>Sharmila</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Woxland</surname>
<given-names>Chaz G.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arguello</surname>
<given-names>Meztli</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Truitt</surname>
<given-names>Morgan L.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sonenberg</surname>
<given-names>Nahum</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruggero</surname>
<given-names>Davide</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fruman</surname>
<given-names>David A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Molecular Biology &amp; Biochemistry, and Institute for Immunology, University of California Irvine, Irvine, CA 92617, USA</aff>
<aff id="A2"><label>2</label>Department of Medicine, University of California San Diego, San Diego, CA 92103, USA</aff>
<aff id="A3"><label>3</label>Department of Biochemistry and Goodman Cancer Research Centre, McGill University, Montreal, Quebec H3A 1A3, Canada</aff>
<aff id="A4"><label>4</label>School of Medicine and Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author. <email>dfruman@uci.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>25</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>30</day>
<month>11</month>
<year>2016</year>
</pub-date>
<volume>9</volume>
<issue>430</issue>
<fpage>ra57</fpage>
<lpage>ra57</lpage>
<!--elocation-id from pubmed: 10.1126/scisignal.aad8463-->
<abstract>
<p id="P1">Rapamycin has been used as a clinical immunosuppressant for many years; however, the molecular basis for its selective effects on lymphocytes remains unclear. We investigated the role of two canonical effectors of the mammalian target of rapamycin (mTOR), ribosomal S6 kinases (S6Ks) and eukaryotic initiation factor 4E (eIF4E)–binding proteins (4E-BPs). S6Ks are thought to regulate cell growth (increase in cell size) and 4E-BPs are thought to control proliferation (increase in cell number), with mTORC1 signaling serving to integrate these processes. However, we found that the 4E-BP–eIF4E signaling axis controlled both the growth and proliferation of lymphocytes, processes for which the S6Ks were dispensable. Furthermore, rapamycin disrupted eIF4E function selectively in lymphocytes, which was due to the increased abundance of 4E-BP2 relative to that of 4E-BP1 in these cells and the greater sensitivity of 4E-BP2 to rapamycin. Together, our findings suggest that the 4E-BP–eIF4E axis is uniquely rapamycin-sensitive in lymphocytes, and that this axis promotes clonal expansion of these cells by coordinating growth and proliferation.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>